title: [Analisis of the budget impact of adalimumab and etanercept in rheumatoid arthritis and spondyloarthropathies].
abstract: OBJECTIVE
  To assess the economic impact derived from the widening of the administration intervals of adalimumab (ADA) and etanercept (ETN) for the treatment of rheumatoid arthritis (RA) and spondyloarthropathies (SAP) at our working environment.
  
  
  METHODS
  A budget impact model (BIM) was developed to estimate the economic impact that would have widening the usual administration intervals of ADA, 40 mg every 2 weeks and ETN, 50 mg weekly (scenario A), to ADA, 40 mg every 3 weeks, and ETN, 50 mg every 2 weeks (scenario B) according to the guidelines and recommendations applied to these studies, specifying the target population, the study perspective, the temporal horizon, and analysing the study robustness by a threshold univariate sensitivity analysis.
  
  
  RESULTS
  71 patients were included in the study. The application of the BIM showed yearly savings for ADA and ETN of 19.784 ??and 38.271 ?, respectively. The net cost, that is to say the saving that this would imply within the temporal horizon considered (2 years), was 116.110 ?. The sensitivity analysis showed that the estimated BIM for the study period was very robust since the net result in the different scenarios varied very little, being negative in the new scenarios.
  
  
  CONCLUSIONS
  widening the administration intervals of ADA and ETN to every 3 weeks and 2 weeks respectively, would be a strategy that would allow generating savings in the hospital budget close to 116.110 ??for the temporal horizon considered, achieving this way optimization of the treatment with these two drugs.
authors.forename: A
authors.initials: A
authors.lastname: González Álvarez
authors.forename: M
authors.initials: M
authors.lastname: Gómez Barrera
authors.forename: J
authors.initials: J
authors.lastname: Borrás Blasco
authors.forename: E J
authors.initials: EJ
authors.lastname: Giner Serret
mesh_terms: D000068879:Adalimumab; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000191:economics*; D002017:Budgets / Q000706:statistics & numerical data*; D017046:Cost Savings; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data*; D000068800:Etanercept; D005260:Female; D005102:Health Expenditures / Q000706:statistics & numerical data; D006786:Hospitals, Urban / Q000191:economics; D006801:Humans; D007074:Immunoglobulin G / Q000008:administration & dosage / Q000191:economics* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018803:Models, Economic; D009313:National Health Programs / Q000191:economics; D017410:Practice Guidelines as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000008:administration & dosage / Q000627:therapeutic use; D013030:Spain; D025242:Spondylarthropathies / Q000188:drug therapy / Q000191:economics*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000068879:Adalimumab; D000068800:Etanercept